In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.Contributors:Joleen Hubbard MDCathy Eng, MDStephanie Andrews, MS, APRN-CMs Andrews: fees for non-CME/CE services: Genentech.Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ver todos los episodios